Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Begent Cream is a topical combination dermatological preparation containing the synthetic corticosteroid betamethasone dipropionate and the aminoglycoside antibiotic gentamicin sulfate. Betamethasone dipropionate is a highly potent glucocorticoid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects by binding to glucocorticoid receptors and inhibiting inflammatory transcription factors. Gentamicin sulfate is a broad-spectrum antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and exerting bactericidal activity. Begent Cream is developed by Global Pharmaceuticals and is indicated for the treatment of inflammatory skin conditions, such as eczema, psoriasis, and dermatitis, that are complicated by or at risk of secondary bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone dipropionate + gentamicin sulfate.